These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 24572833

  • 1. Acylated and unacylated ghrelin administration to blunt muscle wasting.
    Reano S, Graziani A, Filigheddu N.
    Curr Opin Clin Nutr Metab Care; 2014 May; 17(3):236-40. PubMed ID: 24572833
    [Abstract] [Full Text] [Related]

  • 2. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice.
    Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, Prodam F, Ronchi G, Fagoonee S, Fornaro M, Chianale F, Baldanzi G, Surico N, Sinigaglia F, Perroteau I, Smith RG, Sun Y, Geuna S, Graziani A.
    J Clin Invest; 2013 Feb; 123(2):611-22. PubMed ID: 23281394
    [Abstract] [Full Text] [Related]

  • 3. Ghrelin: from discovery to cancer cachexia therapy.
    Molfino A, Formiconi A, Rossi Fanelli F, Muscaritoli M.
    Curr Opin Clin Nutr Metab Care; 2014 Sep; 17(5):471-6. PubMed ID: 24905862
    [Abstract] [Full Text] [Related]

  • 4. Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle.
    Yu AP, Pei XM, Sin TK, Yip SP, Yung BY, Chan LW, Wong CS, Siu PM.
    Acta Physiol (Oxf); 2014 May; 211(1):201-13. PubMed ID: 24581239
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.
    Koopman R, Ryall JG, Church JE, Lynch GS.
    Curr Opin Clin Nutr Metab Care; 2009 Nov; 12(6):601-6. PubMed ID: 19741516
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Drugs of Muscle Wasting and Their Therapeutic Targets.
    Sakuma K, Yamaguchi A.
    Adv Exp Med Biol; 2018 Nov; 1088():463-481. PubMed ID: 30390265
    [Abstract] [Full Text] [Related]

  • 10. Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment.
    Ali S, Chen JA, Garcia JM.
    Curr Opin Support Palliat Care; 2013 Dec; 7(4):368-75. PubMed ID: 24145681
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical perspectives for ghrelin-derived therapeutic products.
    Allas S, Abribat T.
    Endocr Dev; 2013 Dec; 25():157-66. PubMed ID: 23652401
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antifibrotic activity of acylated and unacylated ghrelin.
    Angelino E, Reano S, Ferrara M, Agosti E, Graziani A, Filigheddu N.
    Int J Endocrinol; 2015 Dec; 2015():385682. PubMed ID: 25960743
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ghrelin and the growth hormone secretagogue receptor in growth and development.
    Chanoine JP, De Waele K, Walia P.
    Int J Obes (Lond); 2009 Apr; 33 Suppl 1():S48-52. PubMed ID: 19363508
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.